Composition for curing hyperlipemia

A technology for hyperlipidemia and composition, which is applied in the directions of drug combination, medical preparations containing active ingredients, metabolic diseases, etc., to achieve the effects of good comprehensive effect, convenient use and long duration of curative effect

Inactive Publication Date: 2003-11-26
LUNAN PHARMA GROUP CORPORATION
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the drug's direct inhibition of liver synthesis of VLDL may also be the reason for lowering LDL

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0023] Acipimus 250g

[0024] Lactose 30g

[0025] Sodium carboxymethyl starch 30g

[0026] Microcrystalline Cellulose 18g

[0027] 6% PVP in absolute ethanol 100g

[0028] Magnesium Stearate 2g

[0029] Preparation process: Acipimox is passed through a 100-mesh sieve, lactose, sodium carboxymethyl starch, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescribed amount of acipimox, lactose, sodium carboxymethyl starch, and microcrystalline cellulose is weighed Mix the ingredients evenly, add an appropriate amount of 6% PVP absolute ethanol solution to granulate, dry at 60°C, sieve the dry granules with a 16-mesh sieve, and add the prescribed amount of magnesium stearate to the dry granules. b.

[0030] Rosuvastatin 10g

[0031] Hydroxypropyl Cellulose 30g

[0032] 20g pregelatinized starch

[0033] 6% PVP in absolute ethanol solution 50g

[0034] Glyceryl Behenate 2g

[0035] Preparation process: rosuvastatin is passed through a 100-mesh ...

example 2

[0037] Acipimus 375g

[0038] Hydroxypropyl Methyl Cellulose-4M 40g

[0039] Microcrystalline Cellulose 30g

[0040] 8% PVP in absolute ethanol solution 150g

[0041] Magnesium Stearate 2g

[0042] Preparation process: Acipimox passes through a 100-mesh sieve, hydroxypropyl methylcellulose-4M and microcrystalline cellulose pass through a 80-mesh sieve, and the prescribed amount of acipimox and hydroxypropylmethylcellulose-4M is weighed , the microcrystalline cellulose is mixed evenly, add the absolute ethanol solution of 8%PVP and granulate in right amount, 60 ℃ of drying, 16 mesh sieve dry granules, add the magnesium stearate of recipe quantity in the dry granules. b.

[0043] Rosuvastatin 10g

[0044] Sodium Carboxymethyl Cellulose 30g

[0045] Lactose 20g

[0046] 6% PVP in 95% ethanol solution 50g

[0047] Magnesium Stearate 2g

[0048] Preparation process: rosuvastatin is passed through a 100-mesh sieve, sodium carboxymethylcellulose and lactose are passed through ...

example 3

[0050] Niacin 500g

[0051] Mannitol 10g

[0052] Lactose 40g

[0053] Microcrystalline Cellulose 20g

[0054] 6% PVP in 95% ethanol solution 120g

[0055] Magnesium Stearate 2g

[0056] Preparation process: niacin is passed through a 100-mesh sieve, mannitol, lactose, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescribed amount of niacin, mannitol, lactose, and microcrystalline cellulose is weighed and mixed evenly, and 95% of 6% PVP is added. An appropriate amount of % ethanol solution is granulated, dried at 60° C., and the dry granules are sieved with a 16-mesh sieve, and the prescribed amount of magnesium stearate is added to the dry granules. b.

[0057] Rosuvastatin 10g

[0058] 25g pregelatinized starch

[0059] Mannitol 25g

[0060] 6% PVP in 95% ethanol solution 50g

[0061] Micronized silica gel 2g

[0062] Preparation process: Rosuvastatin is passed through a 100-mesh sieve, pregelatinized starch and mannitol are passed thr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The composition for treating hyperlipemia contains nicotinic acid or its derivative and rosuvastatin in effective amount as the active component. The said nicotinic acid derivative is inositol nicotinate, vitamin E nicotinate or Acipimox. Compared with the medicine with the active component nicotinic acid or its derivative or rosuvastatin, the composition has wonderful raised curative effect.

Description

Technical field [0001] The invention provides a composition of nicotinic acid for treating hyperlipidemia, or a derivative thereof and rosuvastatin. The novel niacin with pharmaceutically active substances, or the combination of its derivatives and rosustatin, can be used to prepare medicines for preventing and treating hyperlipidemia. It belongs to the field of medical technology. Background technique [0002] The main place where the body synthesizes endogenous cholesterol is in the liver (accounting for about 70% of the total). The biosynthesis of cholesterol starts with the condensation of two molecules of acetyl-CoA into acetoacetyl-CoA, which is then condensed with one molecule of acetyl-CoA into 3-hydroxy-3-methylpentanoyl-CoA through the action of hydroxymethylglutaryl-CoA synthase in the cytosol. Diacyl-CoA (HMG CoA). HMGCoA reductase in the cytosol can catalyze the reduction of HMG CoA with a ring-opened hydroxy acid structure to mevalonate, and further generate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/505A61P3/06
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap